On March 9, Tonghua Dongbao Pharmaceutical Co.Ltd(600867) announced that it planned to repurchase no less than 12 million shares (inclusive) and no more than 24 million shares (inclusive) with its own funds through centralized bidding within 6 months from the date when the company’s general meeting considered and approved the share repurchase plan, accounting for 0.60% to 1.19% of the company’s total share capital. The repurchase price shall not exceed 15 yuan / share, and the total amount of funds to be repurchased shall not exceed 360 million yuan (including). This repurchase is based on the management’s confidence in the company’s future development prospects and high recognition of the company’s value. In February, the company just completed the share repurchase of 264 million yuan and the cancellation of 24 million shares.
This is another share repurchase plan released only more than a month later. It will also be cancelled after repurchase, which will help to thicken earnings per share and net asset value per unit share, improve shareholders’ return on investment, and is the company’s continuous practice of paying attention to shareholders’ interests and protecting shareholders’ rights and interests. In response to investors’ questions on the “SSE E interaction” platform, the company previously said that “the company believes that the stock price is seriously undervalued. Due to the influence of external factors such as market environment and national policies, the stock price may deviate from the fundamentals in a short time, but it is believed that the value of the company will be recognized by the market”.
According to the 2021 annual performance express released by the company, in 2021, its main business resumed rapid growth, its profitability was further improved, and its annual operating revenue was 3.252 billion yuan, a year-on-year increase of 12.45%; The net profit attributable to shareholders of listed companies was 1.334 billion yuan, a year-on-year increase of 43.40%.
The company is also commendable in R & D. In terms of innovative drugs, a total of 5 types of innovation have been arranged, 3 of which are in the field of diabetes treatment, and 2 are in the field of gout treatment. Among them, the world’s first clinical phase I trial of SGLT1 / SGLT2 / DPP4 three target inhibitors has been completed, and the first subject has been enrolled; URAT1 inhibitors have also been approved to enter the clinical stage. In addition, many of its products under development were approved for listing last year, including insulin aspart, sitagliptin phosphate, sitagliptin and metformin. Other products such as fourth generation insulin, GLP-1, oral hypoglycemic drugs, and insulin and glp-1ra compound preparations have made varying degrees of progress Tonghua Dongbao Pharmaceutical Co.Ltd(600867) said that it has the most comprehensive product layout in China, which will meet the needs of patients with different stages and characteristics through multi-level product system. At the same time, it has expanded to other endocrine and metabolic fields such as hyperuricemia / gout treatment, and continuously expanded the market space and growth space of products.
The company emphasized the importance of shareholders’ return. On the one hand, it improved shareholders’ return on investment through continuous high dividends, share repurchase and cancellation, on the other hand, it enhanced the company’s core competitiveness, investment value and social value through continuous improvement of new drug innovation and R & D capability and high-quality foreign cooperation Tonghua Dongbao Pharmaceutical Co.Ltd(600867) in the future, we will continue to unswervingly commit to improving the quality of the company and strive to repay shareholders and society.
